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ORIGINAL ARTICLE

Clinical and Technical Factors Associated with Skin Intrinsic
Fluorescence in Subjects with Type 1 Diabetes from the
Diabetes Control and Complications Trial/Epidemiology
of Diabetes Interventions and Complications Study
Patricia A. Cleary, MS,1 Barbara H. Braffett, PhD,1 Trevor Orchard, MD,2 Timothy J. Lyons, MD,3
John Maynard, MS,4 Catherine Cowie, PhD,5 Rose A. Gubitosi-Klug, MD, PhD,6 Jeff Way, BS,4
Karen Anderson, MS,1 Annette Barnie, RN, CDE,7 Stephan Villavicencio, MS,1
and the DCCT/EDIC Research Group*

Abstract
Background: The Diabetes Control and Complications Trial (DCCT)/Epidemiology of Diabetes Interventions and Complications (EDIC) studies have established multiyear mean hemoglobin A1c (HbA1c) as predictive of microvascular complications in persons with type 1 diabetes. However, multiyear mean HbA1c is not always available in the clinical setting. Skin
advanced glycation end products (AGEs) are thought to partially reflect effects of hyperglycemia over time, and measurement of skin AGEs might be a surrogate for multiyear mean HbA1c. As certain AGEs fluoresce and skin fluorescence has
been demonstrated to correlate with the concentration of skin AGEs, noninvasive measurement by skin intrinsic fluorescence
(SIF) facilitates the exploration of the association of mean HbA1c and other clinical/technical factors with SIF using the
detailed phenotypic database available in DCCT/EDIC.
Subjects and Methods: Of the subjects, 1,185 (53% male) had measurements of SIF during years 16/17 of EDIC with mean age
and diabetes duration of 51.5 and 29.8 years, respectively. SIF measurements were obtained on the underside of the forearm
near the elbow using a skin fluorescence spectrometer. Demographic data and health history were self-reported, and an
annual standardized examination measured clinical status. Linear regression models were constructed to identify significant
clinical and technical factors associated with SIF, and the final models only used factors that were significant.
Results: SIF ranged from 8.7 to 54.0 arbitrary units and was log-normally distributed. Log(SIF) correlated more with mean
HbA1c as the time period increased. In multivariate analyses log(SIF) was significantly associated with mean HbA1c, age,
estimated glomerular filtration rate < 60 mL/min/m2, smoking status, skin tone, and clinic latitude <37 N.
Conclusions: SIF reflects age, mean HbA1c over time, smoking, and renal damage, which are known risk factors for diabetes
complications.
Introduction
he Diabetes Control and Complications Trial1
(DCCT) and the Epidemiology of Diabetes Interventions
and Complications2 (EDIC) study have extensively characterized a cohort of 1,441 subjects with type 1 diabetes mellitus

T

(T1DM) over 28 years, resulting in a comprehensive phenotypic history of clinical risk factors, glycemic exposure, and
development of micro- and macrovascular complications. The
DCCT/EDIC studies have clearly demonstrated the causal role
of glycemic exposure, as assessed by mean hemoglobin A1c
(HbA1c), in development of diabetes-related microvascular
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SIF CLINICAL AND TECHNICAL FACTORS IN EDIC
complications. Skin advanced glycation end products (AGEs)
are formed in part by exposure to glucose over time and have
been shown to be independently associated with and predictive of the microvascular complications of diabetes.3,4 Certain
skin AGEs fluoresce (e.g., pentosidine, crosslines), facilitating
noninvasive measurement5–7 that could be used in clinical
studies or settings.
Although the pathogenesis is poorly understood,
hyperglycemia-associated tissue damage operates through
formation and accumulation of AGEs.8,9 AGEs are the products of free radical oxidation between reducing sugars and
amino groups in proteins. AGE formation is considered a
process that is enhanced in diabetes by elevated glucose
concentrations and oxidative stress.10,11 Studies have focused
on AGE modification of skin collagen, which may reflect
AGE-mediated tissue damage elsewhere in the body, including vessel wall stiffening, basement membrane thickening,
and demyelination of nerve fibers.11–13
Skin AGE content accumulates with age, and this accumulation is accelerated in diabetes.14 In addition, studies have
shown that AGE accumulation is higher with compromised
kidney function because of reduced ability to clear AGEs from
the body.15
Skin intrinsic fluorescence (SIF) provides an opportunity for
noninvasive measurement5–7,16 and enables larger studies
than possible with biopsies and chemical assays of skin AGEs.
SIF may be affected by technical factors such as environmental
sun exposure and skin tone because the melanin and hemoglobin in skin can absorb the light used to excite skin fluorescence more strongly than the emitted fluorescence, leading to
distortion of SIF.5,6 The geographically diverse DCCT/EDIC
study afforded the opportunity to examine the influence of
these technical factors on SIF in concert with numerous clinical
factors contained in the 28-year phenotypic history available in
this cohort. The DCCT/EDIC study also facilitates examination of the association of SIF with time-weighted mean HbA1c
to determine if SIF is an indicator of historic glycemic exposure
that is often unavailable in normal clinical settings.
We therefore used the detailed phenotypic history available
in the DCCT/EDIC study and measurements of SIF on 1,185
EDIC participants during years 16–17 to determine the association with SIF of glycemic exposure, other clinical factors, and
technical factors that may impact the SIF measurement.
Subjects and Methods
Study population
The inclusion and exclusion criteria, treatment protocol,
and baseline characteristics of the DCCT cohort have been
previously described.17,18 In brief, 1,441 subjects with T1DM
who were 13–39 years old were recruited between 1983 and
1989. The primary prevention cohort consisted of 726 subjects
who, at study baseline, had no retinopathy, a urinary albumin
excretion rate (AER) of <40 mg/24-h period, and diabetes
duration of 1–5 years. The secondary intervention cohort
consisted of 715 subjects who had very mild to moderate
nonproliferative retinopathy, urinary AER £200 mg/24-h
period, and diabetes duration 1–15 years. Individuals with
hypertension (defined by systolic blood pressure of ‡140 mm
Hg or diastolic blood pressure of ‡90 mm Hg), a history of
symptomatic ischemic heart disease, major electrocardiogram
abnormalities, or severe hypercholesterolemia were excluded.
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The 711 patients randomized to intensive treatment received either multiple daily insulin injections or continuous
subcutaneous insulin infusion with external insulin pumps,
along with frequent self-glucose monitoring. Conventional
therapy patients (n = 730) were treated with one or two daily
insulin injections and daily urine or blood glucose testing. The
intensive and conventional treatment groups maintained
median HbA1c levels of 7.0% and 9.0%, respectively, during
the 6.5-year mean DCCT follow-up. In 1994, 1,375 subjects
(96% of the surviving cohort) agreed to participate in the
EDIC study to examine DCCT treatment effects on longerterm complications of diabetes.2 With the initiation of the
EDIC study, conventional treatment participants were offered
instruction in intensive therapy. EDIC participants were
evaluated annually.
For the SIF substudy, all living subjects who participated
during year 16 or 17 were eligible for inclusion unless they
met exclusion criteria: history of extreme photosensitivity
(n = 11), skin cancer (n = 10), no informed consent (n = 5),
birthmarks, tattoos, skin rashes, or chemical hair removal
(n = 5), or missing the study participation window (n = 73). As
a result, 1,185 of 1,289 active EDIC participants were included
(92%).
SIF measurement
Duplicate measurements of SIF were obtained from the
skin on the underside of the left forearm using a SCOUT skin
fluorescence spectrometer (VeraLight, Inc., Albuquerque,
NM). SIF was excited with a light-emitting diode centered
at 375 nm and was detected over the emission range of
435–655 nm. Skin reflectance was assessed with a white lightemitting diode over the 435–655 nm spectral region. The measured skin reflectance was used to compensate for absorbance
due to melanin and hemoglobin as well as subject-specific
light scattering using the intrinsic fluorescence correction5
formula expressed in Eq. 1:
fxm ¼

Fxm
Rkx Rkmm

(1)

where the measured fluorescence, Fxm, is divided by reflectance values from the excitation and white light-emitting diodes, Rx and Rm, respectively. The reflectance values are
adjusted by the dimensionless exponents, kx and km. For these
analyses, the 375-nm excited fluorescence was used with kx set
to 0.6 and km set to 0.2. The resulting intrinsic fluorescence,
fxm, was integrated over the 435–655 nm spectral region and
multiplied by 1,000 to represent SIF, reported in arbitrary
units (AU). These values of kx and km were previously determined to be relevant for the 375-nm excited fluorescence,
which had the strongest association with diabetes-related
complications in the Pittsburgh Epidemiology of Diabetes
Complications cohort.19
Clinical outcomes
Demographic data and health history were self-reported. A
physical examination measured clinical status. Laboratory
measurements were performed at the DCCT/EDIC Central
Biochemistry Laboratory as previously described.17 HbA1c
was measured every 3 months during the DCCT and yearly
during the EDIC study.2,17 Long-term stability of the HbA1c
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assay has been described.20 AER was measured annually
during the DCCT and in alternate years during the EDIC
study using a timed 4-h urine collection and expressed per
24-h period.2,17 Serum lipids were measured using enzymatic
methods from fasting samples obtained yearly during the
DCCT and in alternate years during the EDIC study. Serum
creatinine was measured annually in the DCCT/EDIC. Estimated glomerular filtration rate (eGFR) was calculated from
serum creatinine specific for age, sex, and race using the
Chronic Kidney Disease–Epidemiology Collaboration equation.21 Time-weighted eGFR was computed by taking the
mean of the eGFR values for each subject over the entire
DCCT/EDIC time period up to the year the SIF measurement
was performed.22 For all linear regression models a categorical variable of any eGFR <60 mL/min/m2 from DCCT enrollment to date of the SIF measurement was used because it
was the renal variable most strongly correlated with SIF.
Clinic latitude was hypothesized to be a surrogate for potential differences in vitamin D levels due to sun exposure and
was incorporated into the data analysis as a categorical variable, with EDIC clinics below latitude 37 N designated as
southern clinics (n = 7) and those above as northern clinics
(n = 21).23–26 Skin tone was considered a measure of the light
reflected by the subject’s skin. Skin tone was measured by the
SCOUT device across the 435–655 nm spectral region and
was calculated by summing light reflectance in that range.
Smoking status was determined by subject self-report and
categorized as ‘‘never smoked’’ (£100 cigarettes in a subject’s
lifetime), ‘‘previous smoker’’ (quit ‡1 year ago), or ‘‘current
smoker.’’ Subject age at the time of the SIF measurements was
used for all analyses. Mean HbA1c for a given number of
years was calculated by taking the mean of the HbA1c values
of the given time period. Total mean HbA1c was calculated
by summing (DCCT/EDIC eligibility HbA1c · duration of
diabetes at study baseline), (DCCT mean HbA1c · years
of follow-up in DCCT), and (EDIC mean HbA1c · years of
follow-up in EDIC) and dividing by total duration of diabetes.
Statistical analyses
Demographic and clinical characteristics were compared
using the Wilcoxon rank-sum test to evaluate treatment group
differences for ordinal and numeric variables. The contingency v2 test was used for categorical variables. The first SIF
measurement per subject was used for all analyses except the
intrasubject, same-day variation in SIF, which was assessed
using the method of the Hoorn study.27 The correlations between log(SIF) and EDIC phenotype data were computed by
linear regression, and variables that were significantly correlated with log(SIF) were used in multivariate analysis. Multivariate linear regression of log(SIF) on various glycemic
exposure intervals was simultaneously adjusted for the
following significant variables: age, any eGFR <60 mL/min/
m2, smoking status, skin tone, and clinic latitude <37 N. In
each linear regression model, the variance contribution of
each term was estimated and reported as a squared semipartial correlation coefficient.
Results
At the time of SIF measurement, the population had a mean
age of 51.5 years and diabetes duration of 29.8 years (Table 1).
The mean SIF values did not differ significantly by DCCT
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treatment cohort (P = 0.82) or by gender (P = 0.62). However,
there was a significant difference in SIF between the primary prevention (22.2 – 4.8 AU) and secondary intervention (23.2 – 4.8 AU) cohorts of the DCCT (P < 0.0001), which
is explained by the younger age of the primary prevention
cohort (51 – 7 vs. 52 – 7 years, P < 0.01) and, at the start of
DCCT, the shorter duration of diabetes (1–5 years vs. 1–15
years) and absence of renal compromise (AER <40 mg/24-h
period).
In the 1,185 EDIC subjects with SIF measurement, the intraday Hoorn coefficient of variation was 4.2%, and the between-measurement correlation was 0.963 (R2 = 0.927), which
explains 7.3% of the total variance in the SIF measurement.
The range of SIF values in the EDIC cohort was 8.7–54.0 AU,
with a mean value of 22.7 – 4.8 AU. The distribution had
a log normal characteristic, so SIF was natural logarithmtransformed for further statistical analyses, resulting in a
mean value of the log(SIF) of 3.10 – 0.21 AU.
The correlations (R2) of log(SIF) with increasing lengths of
glycemic exposure as assessed by mean HbA1c are reported
in Table 2. Each row represents a different interval of glycemic
exposure, ranging from the most recent 5 years of EDIC to the
subject’s glycemic exposure from entry into DCCT to the most
recent year of EDIC (29.8 – 4.9 years). For all time intervals, the
intensive therapy group showed a lower correlation with
current SIF than did the conventional therapy group. The
correlation of log(SIF) with glycemic exposure increased with
increasing length of glycemic exposure from an R2 of 0.035 for
the most recent 5 years of EDIC to 0.063 for all of the EDIC
study. As shown in Table 2, the trend of increasing correlation
with time holds true for all time periods in the conventional
therapy group, but in the intensive therapy group, the addition of the DCCT period to the EDIC period disrupts the
trend, resulting in lower correlation.
To determine the clinical factors associated with log(SIF),
univariate and multivariate associations were examined for
factors that could be influential, including time-weighted
mean HbA1c, age, gender, body mass index, DCCT treatment
group, DCCT cohort assignment, duration of diabetes, use of
statins at any time, time-weighted mean high-density lipoprotein cholesterol, low-density lipoprotein cholesterol, and
triglycerides, time-weighted serum creatinine, time-weighted
AER, any eGFR <60mL/min/1.73 m2, smoking status, timeweighted mean diastolic and systolic blood pressure, use of
antihypertensive medications at any time, measure of skin
tone, and EDIC clinic latitude >37 N. Univariate analysis
found significant correlations with the above variables (Table
1) with the exceptions of gender, body mass index, highdensity lipoprotein cholesterol, and diastolic blood pressure.
In addition, we observed a loss of correlation of log(SIF) with
time-weighted eGFR for the subset of those with an eGFR
<60 mL/min/m2 (R2 = 0.0015, P = 0.93, n = 7), whereas timeweighted eGFR was significantly correlated with log(SIF) for
those with an eGFR ‡60 mL/min/m2 (R2 = 0.0790, P < 0.0001,
n = 1,178).
Through multivariate analysis (see Table 1), we found the
following clinical/technical factors significantly associated
with log(SIF): glycemic exposure, age, any eGFR <60 mL/
min/m2, smoking status, skin tone, and clinic latitude.
These variables were included in the multivariate models for
log(SIF). Because there was not a significant interaction due to
DCCT treatment group or primary versus secondary cohort,
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573
22.7 – 4.9
308 (54)
51.0 – 6.9
29.5 – 4.9
28.3 – 4.9
294 (51)
255.6 – 48.8
427 (75)
352 (61)
149 (26)
72 (13)
8 (1)
0.8 – 0.2
61.0 – 183.7
2.7 – 0.9
44 (8)
329 (57)
107.9 – 21.0
55.3 – 12.1
83.1 – 42.1
74.1 – 5.1
118.5 – 8.4
337 (59)
7.9 – 1.2
7.8 – 1.1
7.8 – 1.1
7.9 – 1.0
8.2 – 0.9
8.4 – 0.9

612
22.6 – 4.7
317 (52)
51.9 – 6.9
30.0 – 4.9
29.4 – 9.3
298 (49)
260.4 – 46.8
444 (73)
372 (61)
154 (25)
86 (14)
6 (1)
0.8 – 0.2
35.2 – 124.0
2.5 – 0.7
40 (7)
360 (59)
55.3 – 13.4
109.7 – 19.9
86.6 – 42.2
74.4 – 5.2
118.8 – 8.1
340 (56)
7.9 – 1.2
7.9 – 1.1
7.9 – 1.1
8.0 – 1.1
7.8 – 0.9
8.0 – 0.9

Conventional

0.1637
0.1293
0.7549
< 0.0001
< 0.0001

0.3392

0.3991
0.6217
0.2575

0.5080
0.4565
< 0.0001
0.0002
0.4436
0.6238
0.7300
0.1789
0.0389

0.5006
0.0203
0.0990
0.0635
0.3681
0.0513
0.4423
0.7436

—
0.8207

P value

7.9 – 1.1
7.9 – 1.1
8.0 – 1.0
8.0 – 1.0
8.2 – 0.9

7.9 – 1.2

74.3 – 5.2
118.7 – 8.3
677 (57)

724 (61)
303 (26)
158 (13)
14 (1)
0.8 – 0.2
47.7 – 156.1
2.6 – 0.8
84 (7)
689 (58)
55.3 – 12.8
108.9 – 20.5
84.9 – 42.2

625 (53)
51.5 – 6.9
29.8 – 4.9
28.9 – 7.5
592 (50)
258.1 – 47.8
871 (74)

1,185
22.7 – 4.8

Overall

0.035
0.046
0.063
0.058
0.070

0.022

< 0.001
0.025
0.014

0.013
0.019
0.019
0.026
0.056
0.005
< 0.001
0.013
0.008

< 0.001
0.136
0.015
< 0.001
0.014
0.015
0.017
0.065

Univariate R2
with log(SIF)

< 0.0001
< 0.0001
< 0.0001
< 0.0001
< 0.0001

< 0.0001

0.8704
< 0.0001
< 0.0001

< 0.0001
< 0.0001
< 0.0001
< 0.0001
< 0.0001
0.0130
0.9841
< 0.0001
0.0018

0.8482
< 0.0001
< 0.0001
0.6615
< 0.0001
< 0.0001
< 0.0001
< 0.0001

P value

Not used
Not used
Not used
Not used
0.043

Not used

< 0.001
< 0.001
< 0.001

Not used
Not used
Not used
Not used
0.017
0.001
Not used
Not used
< 0.001

0.003
0.110
< 0.001
< 0.001
< 0.001
0.036
0.015
0.048

—
—

Multivariate R2
with log(SIF)a

—
—
—
—
< 0.0001

—

0.3540
0.5828
0.1907

—
—
—
—
< 0.0001
0.1578
—
—
0.3981

0.0237
< 0.0001
0.2837
0.2181
0.6387
< 0.0001
< 0.0001
< 0.0001

—
—

P value

Data are n (%) or mean – SD values. P values are for treatment group differences comparing former intensive versus conventional therapy based on the contingency v2 test for qualitative variables and
the Wilcoxon rank-sum test for quantitative variables.
a
Data are squared semipartial R2 correlations from a linear regression model regressing log(SIF) on all potential explanatory variables, resulting in a R2 of 0.345 for the full model. Variables that were
redundant or weaker than other similar variables are marked as not used and were not included in the model. Specifically, Epidemiology of Diabetes Interventions and Complications
(EDIC) + DCCT + baseline mean hemoglobin A1c (HbA1c) trumped all other mean HbA1c variables, triglycerides trumped high-density lipoprotein cholesterol (HDLC) and low-density lipoprotein
cholesterol (LDLC), and any estimated glomerular filtration rate (eGFR) <60 mL/min/m2 trumped continuous eGFR, albumin excretion rate (AER), serum creatinine, and end-stage renal disease (ESRD).
b
Current smoker defined as currently smoking or smoking within the last year; ever smoker defined as smoking more than a year ago.
c
Total mean HbA1c is calculated by summing (DCCT/EDIC eligibility HbA1c · duration of diabetes at study baseline), (DCCT mean HbA1c · years of follow-up on DCCT), and (EDIC mean
HbA1c · years of follow-up in EDIC) and dividing by total duration of diabetes.

Total number of patients
SIF (arbitrary units)
Demographic characteristics
Gender (male)
Age (years)
Diabetes duration (years)
Body mass index (kg/m2)
Cohort assignment, primary
Skin tone, arbitrary units
Clinic latitude >37 N
Smokingb
Never smoker
Ever smoker
Current smoker
ESRD
Time-weighted serum creatinine (mg/dL)
Time weighted AER (mg/24-h period)
Time-weighted log(AER)
Any eGFR < 60 mL/min/m2 to date
Ever use of statins (yes vs. no)
Time-weighted HDLC (mg/dL)
Time-weighted LDLC (mg/dL)
Time-weighted triglycerides (mg/dL)
Time-weighted BP (mm Hg)
Diastolic
Systolic
Use of antihypertensive
medications ever
Most recent HbA1c (%)
EDIC mean HbA1c (%)
Last 5 years
Last 10 years
All years
EDIC + DCCT mean HbA1c (%)
EDIC + DCCT + baseline mean HbA1c (%)c

Intensive

Former treatment group

Table 1. Characteristics of the Diabetes Control and Complications Trial (DCCT)/Epidemiology of Diabetes Interventions and Complications Skin
Intrinsic Fluorescence (SIF) Population at the Time of SIF Assessment Overall and by Original DCCT Treatment Group
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Table 2. Log(Skin Instrinsic Fluorescence)
Correlation with Increasing Lengths of Glycemic
Exposure as Assessed by Time-Weighted Mean
Hemoglobin A1c, Stratified by Original Diabetes
Control and Complications Trial Treatment Group
R2 for log(SIF) correlation
with glycemic exposure
Former treatment group
Intensive Conventional Overall
EDIC mean HbA1c
Last 5 years
Last 10 years
All years
EDIC + DCCT mean HbA1c
EDIC + DCCT +
baseline mean HbA1ca

0.027
0.036
0.052
0.041
0.054

0.046
0.059
0.078
0.085
0.094

0.035
0.046
0.063
0.058
0.070

Data are squared semipartial R2 correlations from five separate
linear regression models regressing log(skin intrinsic fluorescence
[SIF]) on various glycemic exposure intervals.
a
Total mean hemoglobin A1c (HbA1c) is calculated by summing
(Diabetes Control and Complications Trial [DCCT]/Epidemiology of
Diabetes Intervention and Control [EDIC] eligibility HbA1c · duration of diabetes at study baseline), (DCCT mean HbA1c · years of
follow-up on DCCT), and (EDIC mean HbA1c · years of follow-up in
EDIC) and dividing by total duration of diabetes.

multivariate models were constructed using the entire SIF
substudy cohort. Table 3 contains the multivariate model
coefficients (b) and semipartial R2 for each significant independent variable in the model for log(SIF). Each column
represents a different interval of glycemic exposure. The
multivariate models for each interval of glycemic exposure
explained 30.8–33.1% (total R2) of the variance and were not
different from each other in their ability to predict log(SIF).
Examining the model coefficients (b) for each time interval,
the model coefficient for time-weighted mean HbA1c increased as the glycemic exposure interval increased, whereas
the model coefficient for any eGFR < 60 mL/min/m2

decreased as the glycemic exposure interval increased. The
model coefficients for age, smoking status, skin tone, and
clinic latitude were essentially constant across the various
glycemic exposure intervals. Similarly, the semipartial R2 for
time-weighted mean HbA1c increased with increasing glycemic exposure, decreased for any eGFR <60 mL/min/m2,
and was essentially constant for age, smoking status, skin
tone, and clinic latitude.
Finally, we compared the correlation of the unadjusted
log(SIF) and the multivariate adjusted log(SIF) with glycemic
exposure covering the longest time interval, from entry into
DCCT to the most recent year of EDIC. As shown in Figure
1A, the Pearson correlation for the unadjusted log(SIF) with
glycemic exposure over this interval (29.8 – 4.9 years) yielded
an r = 0.26, which though relatively weak was highly significant (P < 0.0001). In Figure 1B, the adjusted log(SIF) (model
based on total mean HbA1c, age, eGFR <60 mL/min/m2,
smoking status, skin tone, and clinic latitude) had a higher
Pearson correlation coefficient of r = 0.46, which was both
significant (P < 0.0001) and more significantly correlated than
the unadjusted log(SIF) with glycemic exposure.
Discussion
We found that 33.1% of SIF was explained by the clinical
and technical variables listed in Table 3 and another 7.3% by
measurement-to-measurement variance. Of the former, age
contributed nearly half (14.7%), smoking status 5.2%, skin
tone 3.4%, ‘‘any eGFR’’ < 60 mL/min/m2 1.6%, and clinic
latitude 1.5%. As a measure of glycemic exposure, timeweighted mean HbA1c contributed 4.5%. These data demonstrate that, although there is an increasing correlation
between SIF and longer periods of glycemic exposure, much
of the SIF variance is not explained. Factors other than
glycemic exposure that may influence SIF include age,28,29
individual variation in antioxidant defenses,10 renal damage,4,15,30,31 and smoking.32,33
The majority of SIF variance (60%) was not explained by
study variables. Of the unknown contributing factors, individual variation in oxidative stress and in antioxidant

Table 3. Association of Log(Skin Intrinsic Fluorescence) with Varying Glycemic Exposure Intervals
b (R2) at glycemic exposure interval
EDIC

Mean HbA1c (%)
Age (years)
Any eGFR <60 mL/min/m2 to
date (yes vs. no)
Smoking (current, former, never)b
Skin tone (arbitrary units)
Clinic latitude >37o (south vs. north)
Total R2 (all variables)

Last 5 years

Last 10 years

All years

EDIC + DCCT

EDIC + DCCT
+ baselinea

0.028 (0.023)
0.011 (0.137)
0.140 (0.030)

0.032 (0.027)
0.011 (0.137)
0.133 (0.027)

0.037 (0.033)
0.011 (0.136)
0.122 (0.022)

0.043 (0.038)
0.011 (0.146)
0.113 (0.019)

0.048 (0.045)
0.012 (0.147)
0.106 (0.016)

0.070 (0.058)
0.0008 (0.034)
0.055 (0.014)
0.308

0.069 (0.056)
0.0008 (0.034)
0.057 (0.015)
0.314

0.067 (0.053)
0.0008 (0.034)
0.056 (0.015)
0.320

0.067 (0.053)
0.0008 (0.036)
0.058 (0.015)
0.325

0.066 (0.052)
0.0008 (0.034)
0.057 (0.015)
0.331

Data are b coefficients and squared semipartial R2 correlations from five separate linear regression models regressing log(skin intrinsic
fluorescence) on various glycemic exposure intervals. Each model was simultaneously adjusted for age, any estimated glomerular filtration
rate (eGFR) <60 mL/min/m2, smoking status, skin tone, and clinic latitude.
a
Total mean hemoglobin A1c (HbA1c) is calculated by summing (Diabetes Control and Complications Trial [DCCT]/Epidemiology of
Diabetes Intervention and Complications [EDIC] eligibility HbA1c · duration of diabetes at study baseline), (DCCT mean HbA1c · years of
follow-up on DCCT), and (EDIC mean HbA1c · years of follow-up in EDIC) and dividing by total duration of diabetes.
b
Current smoker defined as currently smoking or smoking within the last year; ever smoker defined as smoking more than a year ago.
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FIG. 1. (A) Unadjusted and (B) adjusted log(skin intrinsic fluorescence [SIF]) versus 25-year mean hemoglobin A1c
(HbA1c). Adjustment was done simultaneously for age, any estimated glomerular filtration rate < 60 mL/min/m2, smoking
status, skin tone, and clinic latitude.
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defenses may be important. As shown in our own10 and other
studies,5 among people without diabetes, the interindividual
rate of accumulation of specific AGE products in skin can vary
by a factor of 2. Also, in both people without diabetes and
those with T1DM, we found similar interindividual variation
in the rate of accumulation of oxidized methionine residues in
skin collagen.10 Taken together, these findings suggest a hypothesis that, in the absence of diabetes, the large variation in
the rate of AGE accumulation is possibly linked to individual
specific oxidative stress. Unfortunately, there is no convenient
measure for ‘‘oxidative stress,’’ so we were unable to assess its
contribution to SIF.
We did find similarities with DCCT skin biopsy data collected in 1992. The article of Monnier et al.3 reports correlations with mean HbA1c and biopsy for the six different AGE
assays after adjustment for age and duration of diabetes that
range from 0.205 (R2 = 0.042) for acid-soluble collagen to 0.440
(R2 = 0.194) for furosine. The adjusted SIF measurement had a
correlation of 0.46 (0.414–0.503) to 25-year mean HbA1c (Fig.
1B), which is of the same magnitude as the furosine correlation, although with the exception of age, the SIF adjustments
were different than those used for furosine. It is interesting
that SIF was correlated with the furosine assay (R = 0.25) in the
175 subjects who had both the skin biopsy in 1992 and the SIF
measurement 17–19 years later. Finally, although the 1992
biopsy data showed significant differences in AGE products
between the intensive and conventional therapy groups, there
was no difference in SIF between these groups, possibly due
to study-wide adoption of intensive therapy and the passage
of time.
Loss to follow-up during the EDIC study was higher in
subjects who developed end-stage renal disease or who had a
coronary artery calcification score of > 200 Agatston units,
potentially giving rise to a survivor bias, which may have
eliminated differences in SIF between DCCT treatment
groups for these outcomes (Table 1). However, compared
with the few (n = 104) active DCCT/EDIC participants
without an SIF measure, those examined showed no differences in age (P = 0.97) and duration of diabetes (P = 0.64).
Nonparticipants had a higher mean total (EDIC + DCCT +
baseline) HbA1c (8.4 – 1.0% vs. 8.2 – 0.9%; P = 0.02) (data not
shown).
In subjects without diabetes, chronological age correlates
more strongly with SIF (R2 = 0.261)28,29 than in the current
study (R2 = 0.147). We hypothesize that the higher and more
variable glycemic exposure in subjects with T1DM as well as
increased likelihood of compromised renal function contributed to the weakened correlation of chronological age with
SIF in the EDIC SCOUT substudy cohort. Several studies have
shown that renal failure leads to increased levels of skin AGEs
independent of glycemic control, and the combination of diabetes plus renal failure can lead to high levels of skin AGEs
and SIF.15,30,31
We hypothesized the variance explained by skin tone was
due to imperfections in the intrinsic correction of the measured fluorescence. To test this hypothesis, we changed the
intrinsic correction coefficient, kx, from a value of 0.6 to 0.8 to
compute new SIF values and then rebuilt the multivariate
models. For the new SIF variable, the model R2 increased from
0.33 to 0.46, and the variance explained by skin tone increased
from 0.034 to 0.161, whereas the variance explained by the
other model variables decreased. This analysis confirmed that
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the primary function of the skin tone variable was to compensate for imperfections in the intrinsic correction.
The clinic latitude variable was used to denote subjects who
attended EDIC clinics above 37 N latitude. As shown in the
multivariate analysis, clinic latitude did contribute to a small
but statistically significant portion of the variance in SIF.
However, we cannot definitively say whether this was due to
differences in vitamin D, sun exposure, genetics, or lifestyle.
Approximately 13% of the study cohort were current
smokers, and another 26% were former smokers. As smoking
is known to enhance AGE formation and is a source of oxidative stress,28 the finding that smoking is a contributor to the
variance in SIF is consistent with the literature.
Imperfections of SIF that could contribute to the unexplained variance include the superposition of epidermal
fluorescence from NADH and FAD28 on dermal AGE fluorescence and interday, within-subject measurement variance.
As NADH and FAD are not as stable as dermal AGEs and
their levels fluctuate in response to changes in metabolism
and oxidative stress,34 their superposition on the dermal AGE
signal could reduce the reflection of glycemic exposure in SIF
because the SIF algorithm only takes into account the intensity
of the fluorescence and not the spectral shapes.
Finally, we tested to see if instrument bias was a source of
error by adding clinic number to the multivariate model because there was a one-to-one mapping between instruments
and clinics. This test showed that instrument bias was not a
significant contributor to the overall variance in SIF.
Strengths of this study include the excellent characterization of 92% of all living EDIC subjects. Potential weaknesses
include the absence of measures of smoking by pack-years
and the absence of measures of long-term oxidative stress. In
addition, there are gaps in the HbA1c history due to annual
measurement of HbA1c during the EDIC study instead of
quarterly during the DCCT. Finally, use of clinic latitude as an
indicator of vitamin D levels or sun exposure is an approximation.
Conclusions
In the DCCT/EDIC cohort, clinical factors significantly
associated with SIF include age, smoking status, timeweighted mean HbA1c, skin tone, clinic latitude >37 N, and
any eGFR <60 mL/min/m2. The unadjusted SIF is weakly
but significantly correlated (R = 0.26) with glycemic exposure,
and the strength of the correlation increases with increasing
length of glycemic exposure with the exception that the
HbA1c during the DCCT did not contribute to current SIF
values for the intensive treatment group. When SIF is predicted by a multivariate model that uses the aforementioned
clinical factors, the correlation with glycemic exposure becomes modest (R = 0.46).
These findings suggest that SIF may be associated with
diabetes-related complications because it reflects age, longterm glycemic exposure, smoking, and chronic kidney disease, which are known correlates and risk factors.
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